Kevin Balthaser

CIK: 0001957554

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)13 (43.3%)

Derivative conversions

Awards (A)5 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)12 (40.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ACRS

Aclaris Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (30 total)

ACRS
Aclaris Therapeutics, Inc.
Mar 1, 2026
Tax Payment(F)
Direct
677 shares at avg. $2.87$2K
ACRS
Aclaris Therapeutics, Inc.
Mar 1, 2026
Exercise(M)
Direct
2.4K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2026
Exercise(M)
Direct
22K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2026
Tax Payment(F)
Direct
6.4K shares at avg. $3.47$22K
ACRS
Aclaris Therapeutics, Inc.
Feb 2, 2026
Award(A)
Restricted Stock Units
Direct
99.1K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 2, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
346.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2026
Exercise(M)
Direct
14.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2026
Tax Payment(F)
Direct
5K shares at avg. $3.51$17K
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2026
Tax Payment(F)
Direct
4.5K shares at avg. $2.88$13K
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2026
Exercise(M)
Direct
13.2K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 1, 2026
Exercise(M)
Direct
7.5K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 1, 2026
Tax Payment(F)
Direct
2.3K shares at avg. $3.01$7K
ACRS
Aclaris Therapeutics, Inc.
Dec 31, 2025
Tax Payment(F)
Direct
19.9K shares at avg. $3.01$60K
ACRS
Aclaris Therapeutics, Inc.
Dec 31, 2025
Exercise(M)
Direct
73.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Mar 1, 2025
Exercise(M)
Direct
2.4K shares-
ACRS
Aclaris Therapeutics, Inc.
Mar 1, 2025
Exercise(M)
Direct
1.1K shares-
ACRS
Aclaris Therapeutics, Inc.
Mar 1, 2025
Tax Payment(F)
Direct
727 shares at avg. $1.99$1K
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2025
Award(A)
Employee Stock Option (Right to Buy)
Direct
308.2K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2025
Award(A)
Restricted Stock Units
Direct
88.1K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2025
Tax Payment(F)
Direct
5.8K shares at avg. $2.48$14K
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2025
Exercise(M)
Direct
14.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2025
Award(A)
Restricted Stock Units
Direct
40K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2025
Exercise(M)
Direct
13.2K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2025
Tax Payment(F)
Direct
5.1K shares at avg. $2.48$13K
ACRS
Aclaris Therapeutics, Inc.
Jan 1, 2025
Exercise(M)
Direct
7.5K shares-

		Type	Shares	Price		Ownership
Mar 1, 2026	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	677	$2.87	$1,943	Direct
Mar 1, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	2,375	-	$0	Direct
Feb 3, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	22,025	-	$0	Direct
Feb 3, 2026	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	6,449	$3.47	$22,378	Direct
Feb 2, 2026	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	99,100	-	-	Direct
Feb 2, 2026	ACRS Aclaris Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	346,800	-	-	Direct
Feb 1, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	14,750	-	$0	Direct
Feb 1, 2026	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	4,984	$3.51	$17,494	Direct
Jan 2, 2026	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	4,461	$2.88	$12,848	Direct
Jan 2, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	13,200	-	$0	Direct
Jan 1, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	7,500	-	$0	Direct
Jan 1, 2026	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	2,250	$3.01	$6,772	Direct
Dec 31, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	19,934	$3.01	$60,001	Direct
Dec 31, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	73,750	-	$0	Direct
Mar 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	2,375	-	-	Direct
Mar 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	1,100	-	-	Direct
Mar 1, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	727	$1.99	$1,447	Direct
Feb 3, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	308,200	-	-	Direct
Feb 3, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	88,100	-	-	Direct
Feb 1, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	5,816	$2.48	$14,424	Direct
Feb 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	14,750	-	-	Direct
Jan 2, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	40,000	-	-	Direct
Jan 2, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	13,200	-	$0	Direct
Jan 2, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	5,059	$2.48	$12,546	Direct
Jan 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	7,500	-	$0	Direct

1-25 of 30 transactions

About Balthaser Kevin

Balthaser Kevin (SEC CIK 0001957554) files insider reports with the SEC as Chief Financial Officer of Aclaris Therapeutics, Inc. (ACRS).

Signal8 holds 9 ownership filings by Balthaser Kevin, all Form 4s, filed between Sep 4, 2024 and Mar 3, 2026. Those filings report 30 transactions, from Sep 1, 2024 to Mar 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Balthaser Kevin's filings is in WAYNE, PA.

Recent filings by Balthaser Kevin

Mar 1, 2026: Tax withholding of ACRS shares (Form 4, code F).
Mar 1, 2026: Option exercise of ACRS shares (Form 4, code M).
Feb 3, 2026: Option exercise of ACRS shares (Form 4, code M).
Feb 3, 2026: Tax withholding of ACRS shares (Form 4, code F).
Feb 2, 2026: Grants or awards of ACRS derivative securities (2 lines, Form 4, code A).

Other insiders filing for Aclaris Therapeutics, Inc. (ACRS)

Kolbeck Roland Wilhelm, Chief Scientific Officer
SCHIFF ANDREW N, Director
Mehra Anand, Director
Molineaux Christopher P., Director
Humphries William D., Director
MILANO VINCENT, Director

How to read Form 4 transaction codes